[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100342913":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":41,"collaborators":45,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":7,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":7,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Shantou University Medical College","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Chuangzhen Chen, MD","Affiliated Cancer Hospital of Shantou University Medical College","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+86 13923995569","stccz@139.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Cancer Hospital, Shantou University Medical College","RECRUITING","Shantou","Guangdong","515031","China","CN",{"type":28,"coordinates":29},"Point",[30,31],116.67876,23.35489,{"lat":31,"lon":30},[34,36,40],{"name":10,"role":15,"phone":35,"phoneExt":7,"email":17},"86-13923995569",{"name":37,"role":15,"phone":38,"phoneExt":7,"email":39},"Jianzhou Chen, MD","86-13417049908","cjzeoeo@gmail.com",{"name":10,"role":12,"phone":7,"phoneExt":7,"email":7},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Chuangzhen Chen","Deputy Director, Department of Radiation Oncology",[46],{"name":47,"class":6},"University of Oxford","100342913","biomarkers-for-prediction-of-tumor-response-to-radiotherapy-100342913",false,"NCT03744819","Biomarkers for Prediction of Tumor Response to Radiotherapy","Exploration of Potential Biomarkers to Predict Tumor Response to Radiotherapy in Patients With Solid Tumors","Inclusion Criteria:\n\n* Pathological proven diagnosis of solid tumors\n* Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery\n* Patient must provide study-specific informed consent prior to study entry\n\nExclusion Criteria:\n\n* History of autoimmune diseases\n* History of immunotherapy\n* Prior radiation therapy that would result in overlap of planned radiation therapy fields\n* Will receive immunotherapy during the course of radiotherapy\n* Contraindications for biopsy, such as high bleeding risk","ALL",{"count":57,"type":58},100,"ESTIMATED","OBSERVATIONAL","This study aims to explore potential biomarkers for prediction of therapeutic outcomes in patients with solid tumors after radiotherapy",[62],"Solid Tumors","2024-02-03",{"date":65,"type":66},"2024-02-06","ACTUAL",{"date":68,"type":66},"2018-10-29",{"date":70,"type":58},"2026-11-30",{"name":43,"class":6},1]